Understanding Blood Cancers: The TEMPUS AQUARIUS Study
The TEMPUS AQUARIUS Study is an observational study looking at blood cancers like Acute Myeloid Leukemia (AML) and Follicular Lymphoma (FL). This study doesn't involve new treatments; instead, it collects information from your routine care. Researchers will gather molecular (multi-omic) and clinical data from blood samples and leftover tissue or bone marrow during your regular doctor visits. The main goal is to understand how different biological markers in your body are connected to your real-world health outcomes over five years. You can join if you have a diagnosis of AML or FL and are willing to provide samples and consent. This study aims to improve our understanding of these cancers.
- Study design
- This is an observational study, meaning there are no interventions or treatments being tested. It plans to enroll 550 participants.
- What's involved
- You would provide blood samples and leftover tissue or bone marrow during your routine therapy and disease monitoring.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess outcomes over a period of 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
At a glance
Conditions
Where it's being run
9 sites across 7 statesStudy leadership
- Michael Thompson, MD, PhD, FASCO · PRINCIPAL_INVESTIGATOR · Tempus AI
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications.5 years
The goal of this biomarker discovery registry is to assess DNA and RNA expression patterns and potential biomarkers in biospecimens collected at baseline and throughout treatment, with the goal of generating hypotheses about predictive markers for therapy selection, prognostic indicators, and potential mechanisms of resistance to standard-of-care therapies across multiple hematologic indications.